LPCN.US Lipocine Inc

Healthcare Pharmaceuticals USA Stocks
1.71 USD
Close of Nov 15, 2026
1.36 12.37
Market cap
USD 18.9M
P/E
-
P/B
0.89x
ROE
-43.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is LPCN.US undervalued?

Graham number

The Graham number of Lipocine Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Lipocine Inc fundamental analysis

No fundamental analysis for Lipocine Inc yet.

Lipocine Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Lipocine Inc

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs using its proprietary delivery technology. The company offers TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. It also develops LPCN 1154 (BRLIZIO), an oral neuro-steroid in a Phase 3 pivotal trial for postpartum depression; LPCN 1148, a prodrug of testosterone and testosterone laurate that has completed a Pha…

Full company profile